핵산 메틸화 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 유형별, 기술별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Nucleic Acid Methylation Market Growth & Trends:

The global nucleic acid methylation market is anticipated to reach USD 7.77 billion by 2030 and is projected to grow at a CAGR of 14.69% during the forecast period, according to a new report by Grand View Research, Inc. The market is driven by increasing demand for early disease detection, advancements in sequencing technologies, and growing adoption of precision medicine. Rising research in epigenetics, cancer diagnostics, and neurological disorders is fueling market expansion. AI-driven bioinformatics, cost-effective NGS, and mass spectrometry are enhancing data analysis and efficiency. In addition, increasing investments from pharmaceutical and biotech companies, along with government funding for epigenetics research, are accelerating innovation. Expanding applications in drug discovery, personalized medicine, and non-invasive diagnostics further contribute to market growth.

The COVID-19 pandemic accelerated the market by increasing research in viral epigenetics, immune response, and biomarker discovery. It drove demand for advanced sequencing technologies, AI-driven data analysis, and precision medicine. In addition, increased government funding and pharmaceutical investments in molecular diagnostics and drug development further boosted the adoption of methylation-based research and clinical applications. These factors have propelled the growth of the market and are anticipated to propel exponentially over the forecast period.

Moreover, AI integration is anticipated to propel market growth by enhancing data analysis, improving biomarker discovery, and streamlining sequencing workflows. AI-driven bioinformatics enables faster and more accurate interpretation of methylation patterns, supporting early disease detection and personalized medicine. In addition, AI-powered automation reduces research costs, increases efficiency, and accelerates drug discovery, further driving market expansion. Thereby expected to positively impact the growth of the market over the forecast period.

High costs and technical complexity pose significant challenges to the market. Advanced sequencing platforms, bioinformatics tools, and methylation assays require substantial investment, making them less accessible to smaller research labs and emerging markets. In addition, the need for highly skilled personnel, sophisticated data analysis, and expensive reagents further increases operational costs. The integration of automation and AI-driven bioinformatics solutions is improving efficiency, but affordability remains a barrier to widespread adoption, thereby hampering the growth of the market over the forecast period.

Nucleic Acid Methylation Market Report Highlights:

• The kits & reagents segment held the largest market share of 34.89% in 2024 due to their widespread use in methylation analysis, growing demand for epigenetic research, advancements in sequencing technologies, and the need for cost-effective, high-precision diagnostic solutions. On the other hand, services are expected to grow at the fastest CAGR over the forecast period.
• The DNA methylation segment held the largest market share in 2024 due to its crucial role in disease diagnostics, cancer research, and drug development. Growing adoption of DNA methylation biomarkers for early detection, advancements in sequencing technologies, and increasing investment in epigenetics research have further driven its market dominance. On the other hand, RNA methylation is expected to grow at the fastest CAGR over the forecast period.
• In 2024, the next-generation sequencing (NGS) segment is expected to lead the technology market and grow at the fastest CAGR (2025-2030) due to its high accuracy, scalability, and efficiency in analyzing DNA and RNA methylation patterns. Increasing adoption in cancer research, epigenetics studies, and precision medicine, along with advancements in AI-driven bioinformatics and decreasing sequencing costs, are driving its rapid growth. The bisulfite sequencing & PCR-based techniques segment is expected to grow significantly over the forecast period.
• In 2024, the drug discovery & personalized medicines segment is expected to dominate the application market due to its high accuracy, scalability, and efficiency in analyzing DNA and RNA methylation patterns. Increasing adoption in cancer research, epigenetics studies, and precision medicine, along with advancements in AI-driven bioinformatics and decreasing sequencing costs, are driving its rapid growth. On the other hand, clinical diagnostics are expected to grow at the fastest CAGR over the forecast period.
• The pharmaceutical & biotechnological companies segment dominated the end use market in 2024 due to their significant investment in drug discovery, biomarker research, and precision medicine. The growing use of methylation-based technologies for developing targeted therapies, coupled with advancements in sequencing and AI-driven data analysis, has further strengthened their market leadership. On the other hand, hospitals & diagnostic laboratories are expected to grow at the fastest CAGR over the forecast period.
• The North America region dominated the market with a 40.46% share in 2024, driven by strong investments in epigenetics research, advanced healthcare infrastructure, and widespread adoption of precision medicine. The presence of leading biotechnology and pharmaceutical companies, along with regulatory support for methylation-based diagnostics, has further fueled market growth in the region. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Type
  • 1.2.3. Technology
  • 1.2.4. Application
  • 1.2.5. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Nucleic Acid Methylation Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for epigenetic biomarkers
    • 3.2.1.2. RNA methylation as a drug target
    • 3.2.1.3. Advancements in high-throughput methylation analysis
    • 3.2.1.4. Government & private investments in epigenetics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs & technical complexity
• 3.3. Nucleic Acid Methylation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Nucleic Acid Methylation Market: Product & Services Estimates & Trend Analysis

• 4.1. Product & Services Segment Dashboard
• 4.2. Global Nucleic Acid Methylation Market Product & Services Movement Analysis
• 4.3. Global Nucleic Acid Methylation Market Size & Trend Analysis, by Product & Services, 2018 to 2030 (USD Million)
• 4.4. Kits & Reagents
  • 4.4.1. Kits & reagents market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Enzymes
  • 4.5.1. Enzymes market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Instruments & Software
  • 4.7.1. Instruments & software market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Consumables
  • 4.8.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Nucleic Acid Methylation Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. Global Nucleic Acid Methylation Market Type Movement Analysis
• 5.3. Global Nucleic Acid Methylation Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. DNA Methylation
  • 5.4.1. DNA methylation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. RNA Methylation
  • 5.5.1. RNA methylation market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Nucleic Acid Methylation Market: Technology Estimates & Trend Analysis

• 6.1. Technology Segment Dashboard
• 6.2. Global Nucleic Acid Methylation Market Technology Movement Analysis
• 6.3. Global Nucleic Acid Methylation Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 6.4. Next-Generation Sequencing (NGS)
  • 6.4.1. Next-generation sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Bisulfite Sequencing & PCR-based Techniques
  • 6.5.1. Bisulfite sequencing & pcr-based techniques market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Microarray-based Methylation Analysis
  • 6.6.1. Microarray-based methylation analysis market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Mass Spectrometry
  • 6.7.1. Mass spectrometry market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Hybridization-based & Antibody-based Detection
  • 6.8.1. Hybridization-based & antibody-based detection market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Nucleic Acid Methylation Market: Application Estimates & Trend Analysis

• 7.1. Application Segment Dashboard
• 7.2. Global Nucleic Acid Methylation Market Application Movement Analysis
• 7.3. Global Nucleic Acid Methylation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Drug Discovery & Personalized Medicines
  • 7.4.1. Drug discovery & personalized medicines market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinical Diagnostics
  • 7.5.1. Clinical diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Nucleic Acid Methylation Market: End Use Estimates & Trend Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Nucleic Acid Methylation Market End Use Movement Analysis
• 8.3. Global Nucleic Acid Methylation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Pharmaceutical & Biotechnology Companies
  • 8.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Academic & Research Institutes
  • 8.5.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Hospitals & Diagnostic Laboratories
  • 8.6.1. Hospitals & diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Nucleic Acid Methylation Market: Regional Estimates & Trend Analysis by Product & Services, Type, Technology, Application, and End Use

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 9.4. North America
  • 9.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.7. Norway
    • 9.5.7.1. Key country dynamics
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive scenario
    • 9.5.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key country dynamics
    • 9.5.8.2. Regulatory framework
    • 9.5.8.3. Competitive scenario
    • 9.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.9. Denmark
    • 9.5.9.1. Key country dynamics
    • 9.5.9.2. Regulatory framework
    • 9.5.9.3. Competitive scenario
    • 9.5.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key country dynamics
    • 9.8.4.2. Regulatory framework
    • 9.8.4.3. Competitive scenario
    • 9.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key country dynamics
    • 9.8.5.2. Regulatory framework
    • 9.8.5.3. Competitive scenario
    • 9.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. New England Biolabs
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Thermo Fisher Scientific Inc.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Illumina Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Abcam plc
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Agilent Technologies Inc.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. F. Hoffmann-La Roche Ltd
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Bio-Rad Laboratories, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. QIAGEN
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Exact Sciences Corporation
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. Diagenode Diagnostics S.A.
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives